108994-42-9

Basic information

• Product Name: 2-Chloro-6-(1-methylethoxy)-isonicotinic acid
• Synonyms: 2-Chloro-6-(1-methylethoxy)-isonicotinic acid
• CAS NO: 108994-42-9
• Molecular Weight: 215.636
• Mol File: 108994-42-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Chloro-6-(1-methylethoxy)-isonicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-(1-methylethoxy)-isonicotinic acid(108994-42-9)
• EPA Substance Registry System: 2-Chloro-6-(1-methylethoxy)-isonicotinic acid(108994-42-9)

Safety Data

• Hazardous Substances Data: 108994-42-9(Hazardous Substances Data)

Upstream product

• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 67-63-0 isopropyl alcohol 
• 683-60-3 sodium isopropylate 

Relevant articles and documents

Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists

Sphingosine-1-phosphate receptor 2 (S1PR2) has been identified as a brand-new GPCR target for designing antagonists to reverse 5-FU resistance. We herein report the structural optimization and structure-activity relationship of JTE-013 derivatives as S1PR2 antagonists. Compound 9d was the most potent S1PR2 antagonist (KD = 34.8 nM) among developed compounds. Here, compound 9d could significantly inhibit the expression of dihydropyrimidine dehydrogenase (DPD) to reverse 5-FU-resistance in HCT116DPD and SW620/5-FU cells. Further mechanism studies demonstrated that compound 9d not only inhibited S1PR2 but also affected the transcription of S1PR2. In addition, compound 9d also showed acceptable selectivity to normal cells (NCM460). Importantly, compound 9d with suitable pharmacokinetic properties could significantly reverse 5-FU-resistance in the HCT116DPD and SW620/5-FU xenograft models without obvious toxicity, in which the inhibition rates of 5-FU were increased from 23.97% to 65.29% and 27.23% to 60.81%, respectively. Further immunohistochemistry and western blotting analysis also demonstrated that compound 9d significantly decreases the expression of DPD in tumor and liver tissues. These results indicated that compound 9d is a promising lead compound to reverse 5-FU-resistance for colorectal cancer therapy.

Pyridin-4-yl derivatives as immunomodulating agents

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.